Bristol-Myers Squibb (NYSE:BMY) Given Average Rating of “Hold” by Brokerages

Shares of Bristol-Myers Squibb (NYSE:BMY) have been given an average rating of “Hold” by the nineteen research firms that are covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and three have issued a buy rating on the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $60.00.

A number of brokerages recently weighed in on BMY. Societe Generale downgraded Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research report on Monday, March 11th. StockNews.com downgraded shares of Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a research report on Monday, April 15th. Redburn Atlantic downgraded shares of Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and lowered their target price for the company from $77.00 to $54.00 in a research note on Tuesday, February 6th. William Blair reaffirmed a “market perform” rating on shares of Bristol-Myers Squibb in a report on Monday, April 1st. Finally, Barclays lowered their price objective on Bristol-Myers Squibb from $51.00 to $43.00 and set an “equal weight” rating for the company in a research report on Friday, April 26th.

Bristol-Myers Squibb Trading Up 2.5 %

NYSE BMY opened at $44.75 on Friday. Bristol-Myers Squibb has a one year low of $43.33 and a one year high of $69.10. The company has a debt-to-equity ratio of 2.99, a quick ratio of 0.99 and a current ratio of 1.11. The company has a market capitalization of $90.71 billion, a price-to-earnings ratio of -14.44, a price-to-earnings-growth ratio of 14.82 and a beta of 0.45. The company’s 50-day simple moving average is $49.96 and its two-hundred day simple moving average is $50.43.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported ($4.40) earnings per share (EPS) for the quarter, beating the consensus estimate of ($4.53) by $0.13. The company had revenue of $11.87 billion for the quarter, compared to analyst estimates of $11.45 billion. Bristol-Myers Squibb had a negative net margin of 13.50% and a positive return on equity of 8.83%. Bristol-Myers Squibb’s revenue was up 4.7% compared to the same quarter last year. During the same period last year, the company posted $2.05 earnings per share. Equities analysts forecast that Bristol-Myers Squibb will post 0.59 EPS for the current fiscal year.

Bristol-Myers Squibb Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Wednesday, May 1st. Investors of record on Friday, April 5th were issued a dividend of $0.60 per share. This represents a $2.40 annualized dividend and a yield of 5.36%. The ex-dividend date was Thursday, April 4th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is -77.42%.

Institutional Investors Weigh In On Bristol-Myers Squibb

Several hedge funds have recently bought and sold shares of BMY. OFI Invest Asset Management purchased a new position in Bristol-Myers Squibb in the third quarter valued at $25,000. Milestone Investment Advisors LLC purchased a new position in shares of Bristol-Myers Squibb in the 3rd quarter valued at about $27,000. Northwest Financial Advisors acquired a new position in Bristol-Myers Squibb in the 4th quarter worth about $27,000. Blue Bell Private Wealth Management LLC grew its holdings in Bristol-Myers Squibb by 61.5% in the third quarter. Blue Bell Private Wealth Management LLC now owns 525 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 200 shares during the period. Finally, Accordant Advisory Group Inc purchased a new stake in shares of Bristol-Myers Squibb in the first quarter valued at approximately $31,000. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.